izreloaded
2020-12-30

$Arcturus Therapeutics Ltd.(ARCT)$Arcturus believes cellular responses induced by its ** vaccine candidate will compensate for the underwhelming neutralizing antibody levels in its interim Phase I/II data.

Eng Eong Ooi, a member of Arcturus’ vaccine platform SAB, hypothesized the robust T cell responses were behind the low antibody production following the second 5 µg ARCT-021 administration.

Ooi said their data showed that antibodies were not necessary for protection against SARS-CoV-2. 

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

  • 哈V
    2020-12-30
    哈V
    but when its trial possibly comes to Phase 3 the covid crisis might be over already
    • izreloaded: 
      Unfortunately covid 19 looks like it will stay for a long time. Moderna’s and pfizer’s vaccines for example will not provide a lifetime immunity.
    • izreloaded回复izreloaded: 
      Therefore there is a huge market and opportunIty for vAccines like arcturus which are single dose, cheaper and HaVe rhe abiltTy to prodUce mOre T Cells.
    • izreloaded回复哈V: 
      I hAve positions in biontec, moderna and arcturus.
    • 哈V回复izreloaded: 
      why this vaccine is possibly cheaper? the current RNA vaccine can be as cheap as a few dollars per jab
    • 哈V回复izreloaded: 

      well I used to have positions in biotech and moderna but now hold none of their shares. indeed I shorted mrna the day its vaccine was declared. I've no position in this one. Good luck anyway.

  • izreloaded
    2020-12-30
    izreloaded
    I have positions in biontec, moDerna and arcturus.
发表看法
8